Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS), a precision oncology company focused on RAS/MAPK pathway-driven cancers, will participate in the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. Jonathan E. Lim, M.D., CEO, and David M. Chacko, M.D., CFO, will engage in a "Fireside Chat" at 3:05 PM ET. Investors can register for the live webcast at Evercore.webcasts, with an archived replay available for 30 days on Erasca.com/events.
Erasca aims to develop innovative therapies targeting cancer pathways, leveraging expertise from top pioneers in the field.
Details
News Market Reaction – ERAS
The recorded move for ERAS in the trading session of this news was +3.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Evercore ISI 4th Annual HealthCONx Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a “Fireside Chat” beginning at 3:05 PM Eastern Time on Thursday, December 2, 2021. The company will also participate in one-on-one investor meetings.
Registration and access to the live webcast is available at Evercore.webcasts. An archived replay of the event will be available at Erasca.com/events for 30 days following the webcast.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.